Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up.

Published

Journal Article

PURPOSE: To assess a response to infliximab therapy in childhood uveitis. DESIGN: Retrospective case series. METHODS: We reviewed the course of 16 children with noninfectious uveitis treated with infliximab at an academic medical center. Outcome measures included incidence of uveitis recurrences, proportion of patients achieving zero or two-step decline in ocular inflammation, visual acuity, and proportion discontinuing topical glucocorticoids at zero, three, six, nine, and 12 months of therapy. RESULTS: Of sixteen children (29 affected eyes) with median age 11 years, six had associated extraocular inflammatory conditions. Fifteen of 16 were treated with concomitant methotrexate. Median follow-up was 26 months and median maintenance infliximab dose was 8.2 mg/kg. The median interval between infliximab infusions was 5.6 weeks. At one year, 64% achieved zero ocular inflammation, and 79% had zero inflammation or a two-step decline in inflammation. Topical glucocorticoids were discontinued in 69%, and 58% remained free of uveitis recurrence at one year. Visual acuity remained stable. Infliximab was discontinued in two children, one because of inefficacy and the other because of parental concern about potential side effects. No adverse events occurred. CONCLUSIONS: Sixteen children with chronic, noninfectious uveitis tolerated chronic methotrexate and infliximab therapy. Visual acuity remained stable, control of ocular inflammation improved, and reliance on topical glucocorticoids decreased. High infliximab doses and frequent dosing intervals were necessary to control uveitis.

Full Text

Duke Authors

Cited Authors

  • Ardoin, SP; Kredich, D; Rabinovich, E; Schanberg, LE; Jaffe, GJ

Published Date

  • December 2007

Published In

Volume / Issue

  • 144 / 6

Start / End Page

  • 844 - 849

PubMed ID

  • 17953940

Pubmed Central ID

  • 17953940

International Standard Serial Number (ISSN)

  • 0002-9394

Digital Object Identifier (DOI)

  • 10.1016/j.ajo.2007.08.018

Language

  • eng

Conference Location

  • United States